1. Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors. (February 2017) Authors: Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Iglesias, J.; Fernandez-Teruel, C.; Jandali, U.; Soto-Matos, S.M.; Stathis, A. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CD30 and lymphomas: the clue for four?. (2019) Authors: Mangas, C.; Polino, A.; Stathis, A.; Leoni-Parvex, S.; Marazza, G.; Zucca, E.; Mainetti, C. Journal: European journal of cancer Issue: Volume 119(2019)Supplement 1 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EG‐011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI‐TUMOR ACTIVITY AGAINST LYMPHOMA. (12th June 2019) Authors: Gaudio, E.; Spriano, F.; Tarantelli, C.; Guala, M.; Riveiro, E.; Golino, G.; Lupia, A.; Costa, G.; Rocca, R.; Cascione, L.; Jenni, S.; Tsai, Y.; Bornhauser, B.; Alcaro, S.; Paduano, F.; Trapasso, F.; Zucca, E.; Stathis, A.; Pazzi, N.; Cavalli, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 513 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA. (12th June 2019) Authors: Arribas, A.; Napoli, S.; Gaudio, E.; Cascione, L.; Di Veroli, A.; Tarantelli, C.; Spriano, F.; Zucchetto, A.; Rossi, F.; Rinaldi, A.; Stathis, A.; Stussi, G.; Gattei, V.; Cruciani, G.; Zucca, E.; Rossi, D.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS. (12th June 2019) Authors: Stathis, A.; Mey, U.; Schär, S.; Hitz, F.; Pott, C.; Mach, N.; Krasniqi, F.; Novak, U.; Schmidt, C.; Hohloch, K.; Kienle, D.; Hess, D.; Moccia, A.; Unterhalt, M.; Eckhardt, K.; Hayoz, S.; Rossi, D.; Dirnhofer, S.; Ceriani, L.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT. (12th June 2019) Authors: Ceriani, L.; Pirosa, M.; Stathis, A.; Gritti, G.; Ruberto, T.; Bruno, A.; Moccia, A.; Rambaldi, A.; Ferrari, S.; Giovannella, L.; Hayoz, S.; Mazzucchelli, L.; Dirnhofer, S.; Mamot, C.; Zucca, E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS. (12th June 2019) Authors: Tarantelli, C.; Lange, M.; Gaudio, E.; Cascione, L.; Spriano, F.; Kwee, I.; Arribas, A.; Rinaldi, A.; Jourdan, T.; Berthold, M.; Margheriti, F.; Gritti, G.; Rossi, D.; Stathis, A.; Liu, N.; Zucca, E.; Politz, O.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION. (12th June 2019) Authors: Tarantelli, C.; Spriano, F.; Golino, G.; Gaudio, E.; Scalise, L.; Cascione, L.; Zucca, E.; van Berkel, P.; Stathis, A.; Zammarchi, F.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES. (12th June 2019) Authors: Spriano, F.; Tarantelli, C.; Golino, G.; Gaudio, E.; Scalise, L.; Cascione, L.; Zucca, E.; Van Berkel, P.; Stathis, A.; Zammarchi, F.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL). (12th June 2019) Authors: Zelenetz, A.D.; Jagadeesh, D.; Kenkre, V.P.; Reddy, N.M.; Stathis, A.; Salman, H.S.; Asch, A.S.; Soumerai, J.; Jhangiani, H.S.; Iasonos, A.; Patel, K.; Carter, J.; LLorin‐Sangalang, J.; Pagel, J.M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗